复星医药：控股股东部分股份解除质押，质押比例显著下降——投资者须知重要信息
主要内容摘要
- 控股股东复星高科技于2026年7月21日解除质押6,900万股A股。
- 解除后，复星高科技质押股份余额降至5.23亿股A股，占其持有公司股份的54.43%，占公司总股本的19.60%。
- 复星高科技及其一致行动人合计持有复星医药9.68亿股，占总股本36.24%。解除质押后，合计质押股份为5.23亿股，占所持股份的54.07%。
- 复星高科技确认解除质押股份后存在后续质押计划，未来若有新的质押，将及时披露。
- 此次解除质押无冻结及限售股份，全部为流通A股。
详细解读
2026年7月22日，复星医药（600196.SH）公告称，公司控股股东上海复星高科技（集团）有限公司于2026年7月21日办理了部分A股股份的解除质押手续。本次解除质押股份数量为69,000,000股A股，占复星高科技持有公司股份的7.18%，占公司总股本的2.58%。
解除质押后，复星高科技持有公司股份总数为961,424,455股（A股889,890,955股，H股71,533,500股），约占公司总股本的36.00%。本次解除质押后，复星高科技所质押股份余额为523,275,000股A股，占其所持股份的54.43%，占公司总股本的19.60%。
截至2026年7月21日收市，复星高科技及其一致行动人（包括董监高、复星国际有限公司及相关实际控制人）合计持有公司9.68亿股股份（A股8.90亿股，H股0.78亿股），约占公司总股本的36.24%。本次解除质押后，合计质押股份为5.23亿股A股，占所持股份的54.07%，占公司总股本的19.60%。
公司公告还特别提示，复星高科技确认本次解除质押的股份存在后续质押计划，未来若有新质押，将根据相关法规及时披露。这意味着复星高科技在资金安排上仍有可能继续使用股份质押融资，对公司股价存在一定影响。
值得注意的是，本次解除质押股份中无冻结及限售股份，全部为流通A股，对公司股权结构的流动性无实际负面影响。此外，复星医药也将持续关注控股股东及其一致行动人股份质押的进展，并按法律法规和股票上市地规则的要求，及时履行信息披露义务。
对股东和投资者的重要提示
- 控股股东质押比例显著下降，有助于降低投资者对公司控股权稳定性的担忧。
- 后续股份仍有质押计划，投资者需关注未来质押变动，因大比例股份质押可能影响公司治理及市场信心。
- 本次解除质押事项未涉及限售或冻结股份，对流通盘无影响，但公司控股权质押风险仍需持续关注。
潜在股价影响
本次解除质押将减少控股股东质押比例，理论上有助于市场信心恢复，减少因高比例质押带来的融资平仓风险，从而对复星医药股价产生正面影响。然而，后续仍有质押计划，投资者需关注后续质押和控股权稳定性变化，持续跟踪相关公告。
免责声明
本文仅为信息解读，不构成任何投资建议。投资有风险，决策须谨慎。请投资者关注复星医药后续公告及相关风险提示。
English Version
Fosun Pharma: Controlling Shareholder Releases Pledged Shares, Lowering Pledge Ratio — Key Investor Takeaways
Key Highlights
- On July 21, 2026, Fosun High Technology, the controlling shareholder, released the pledge on 69 million A-shares.
- After the release, the balance of pledged shares dropped to 523 million A-shares, accounting for 54.43% of Fosun High Technology’s holdings and 19.60% of the company’s total share capital.
- Fosun High Technology and its concerted parties collectively hold 968 million shares (36.24% of total), with post-release pledged shares at 523 million, or 54.07% of their holdings.
- Fosun High Technology confirmed plans for future pledges; new pledges will be disclosed in accordance with regulations.
- No restricted or frozen shares were involved in this release; all shares are tradable A-shares.
Detailed Analysis
On July 22, 2026, Fosun Pharma (600196.SH) announced that its controlling shareholder, Shanghai Fosun High Technology (Group) Co., Ltd., released the pledge on 69,000,000 A-shares on July 21, accounting for 7.18% of its holdings and 2.58% of total company shares.
After the release, Fosun High Technology holds a total of 961,424,455 shares (889,890,955 A-shares, 71,533,500 H-shares), representing 36.00% of total share capital. The remaining pledged A-shares stand at 523,275,000, or 54.43% of its holdings and 19.60% of total company shares.
As of the close on July 21, 2026, Fosun High Technology and its concerted parties (including directors, supervisors, senior management, Fosun International Ltd., and actual controllers) collectively hold 967,812,180 shares (890,278,680 A-shares, 77,533,500 H-shares), about 36.24% of total share capital. After this release, the remaining pledged shares are 523,275,000, representing 54.07% of their total holdings and 19.60% of the company’s share capital.
The announcement also emphasizes that Fosun High Technology may initiate new pledges with these released shares in the future and will disclose such actions as required by law. This means that the company may continue to use equity pledge financing, which could impact share price stability.
It is noteworthy that none of the released pledged shares are restricted or frozen; all are tradable A-shares, thus having no negative impact on the liquidity structure. Fosun Pharma will continue to monitor and timely disclose changes in share pledges by the controlling shareholder and its concerted parties.
Critical Information for Shareholders and Investors
- The significant reduction in pledge ratio may alleviate concerns over the stability of controlling rights.
- Investors should remain vigilant for future pledge activities, as high pledge ratios may affect governance and market confidence.
- No impact on tradable share liquidity, but ongoing monitoring of pledge risk is warranted.
Potential Impact on Share Price
The reduction in pledged shares may help restore investor confidence and reduce forced liquidation risk, potentially supporting the share price. However, as future pledges are possible, investors should keep track of further disclosures and assess the risk to controlling rights.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investments carry risks; please make decisions prudently and refer to subsequent Fosun Pharma announcements for updates and risk disclosures.
